Tabula Rasa HealthCare, Inc.: directors' dealings · United States · SEC (Form 4)

About Tabula Rasa HealthCare, Inc.

Tabula Rasa HealthCare, Inc. (TRHC) is a U.S.-listed healthcare company traded on NASDAQ, with headquarters in New Jersey, United States. From an international equity-investor perspective, the company sits in the healthcare technology and pharmacy services segment, combining software, clinical services, and medication management capabilities. TRHC originally built its franchise around medication safety: helping prescribers, pharmacists, and patients optimize drug regimens, reduce adverse drug events, and improve outcomes. Over time, the company evolved from a narrower medication-safety platform into a more integrated care-management and pharmacy services business. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1651561/000155837023013894/trhc-20230630x10q.htm?utm_source=openai)) Its current business model is focused on personalized, precision medication management and pharmacy fulfillment for complex patient populations. According to SEC disclosures, the company provides medication fulfillment services, cloud-based software, pharmacy benefit management solutions, and clinical pharmacist services at the point of care. That makes TRHC a niche operator serving health plans and at-risk provider groups, particularly organizations involved in value-based care and PACE-related programs. In competitive terms, TRHC is not a mass-market pharmacy chain or a large diversified healthcare conglomerate; instead, it targets a specific and operationally demanding slice of the U.S. healthcare ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1651561/000155837023013894/trhc-20230630x10q.htm?utm_source=openai)) A major strategic theme in recent years has been portfolio simplification. TRHC sold PrescribeWellness in 2022 and completed the divestiture of SinfoníaRx and DoseMeRx in 2023, using those transactions to sharpen its focus on core pharmacy-care management markets. This restructuring was important because it reduced business complexity and signaled a deliberate shift toward a more concentrated operating model. The company has also highlighted multi-year customer relationships, including a five-year contract extension with Trinity Health PACE, which underscores the recurring, contract-based nature of part of its revenue base. ([nasdaq.com](https://www.nasdaq.com/press-release/tabula-rasa-healthcare-agrees-to-sell-its-prescribewellness-business-to-transaction?utm_source=openai)) TRHC’s competitive strength lies in its specialized workflow, clinical expertise, and technology-enabled service stack. Its platform is designed for patients with high medication burden and multiple chronic conditions, a segment where medication adherence, safety, and cost control are especially important. The company’s footprint is predominantly in the United States, and its business is closely tied to domestic healthcare reimbursement and managed-care dynamics. Another notable recent development was the announced acquisition by Nautic Partners in 2023, followed by a planned combination with ExactCare Pharmacy, which materially changed the company’s strategic outlook and market perception. Overall, TRHC is best viewed as a U.S. specialty healthcare technology and pharmacy services platform with a focused operating profile and an M&A-shaped recent history. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1651561/000114036123050520/ef20013655_ex99-1.htm?utm_source=openai))